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Abstract The Indian HIV epidemic has not reached the
predicted proportions even after more than 25 years since
the first case of HIV infection was detected in Chennai. An
estimated 2.4 million adults were living with HIV in 2009
and an adult prevalence of HIV was 0.3%. The disease
burden is geographically diverse and has spread to rural
areas also. HIV viruses circulating in India predominantly
belong to HIV-1 subtype C although recombinant strains
and HIV-2 infections have been identified. Tuberculosis is
the commonest opportunistic infection reported from var-
ious parts of the country and HIV-TB co-infection is a
public health challenge. Government of India launched free
antiretroviral treatment (ART) programme 6 years back
which has shown good clinical and immunological
response in HIV infected individuals. Though the drug
resistance monitoring survey has reported effectiveness of
regimen in the programme, adherence remains the key
issue for minimizing the drug resistance. In addition to the
ongoing prevention efforts, India should be poised to
accept and scale up newer preventive tools in a manner
acceptable and feasible in our socio-cultural context in
order to sustain and consolidate the gains that we have
achieved so far.
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Introduction
The year 1986 marked the beginning of Indian AIDS epi-
demic with detection of the first HIV infection in Chennai
and the first AIDS Case in Mumbai [1–3]. This was followed
by the explosive epidemic among intravenous drug users
(IDU) in Manipur in 1989 [4, 5]. Since then the HIV epi-
demic has spread to rural and urban areas, involving high-
risk groups as well as the general population. However, the
Indian epidemic has not reached the predicted proportions
even after more than 25 years since the first case was
detected. The HIV disease burden is geographically diverse
with some districts showing generalized epidemic with
prevalence among ante-natal women being more than 1%
and others with concentrated or low level epidemics.
Epidemiology of HIV Infection in India
Taking note of the Global HIV situation Indian Council of
Medical Research initiated surveys for detection of HIV
infection in different parts of India as early as in 1985 [3].
The epidemiologic data on HIV infection in India is now
available through multiple sources such as the expanded
annual sentinel surveillance among ante-natal women and
populations at high risk of HIV infection, the National
Family Health Survey-3 (NFHS-3), Behavioural Sentinel
Surveillance (BSS) surveys and Integrated Behavioural and
Biological Assessment (IBBA) surveys.
Data on national HIV estimates released by the National
AIDS Control organization (NACO) in December 2010
reveals a decline in overall adult HIV prevalence from
0.41% in 2000 to 0.31% in 2009 with estimated reduction
in new (incident) HIV infections of more than 50% over
the last decade. It is estimated that India had approximately
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0.12 million new HIV infections in 2009, as against 0.27
million in 2000. In all, 11 states showed an estimated adult
HIV prevalence greater than the national average (0.31%).
Manipur showed the highest estimated adult HIV preva-
lence of 1.4%, followed by Andhra Pradesh (0.90%),
Mizoram (0.81%), Nagaland (0.78%), Karnataka (0.63%)
and Maharashtra (0.55%). Delhi, Orissa, West Bengal,
Chhattisgarh & Pondicherry have shown estimated adult
HIV prevalence of 0.28–0.3%. All other states/union ter-
ritories have lower levels of HIV prevalence (Fig. 1) [6].
The Indian epidemic is primarily driven by unprotected
sex in commercial setting [7] in most parts of the country
while intravenous drug use is a major driver in the North-
East. Recently released data have shown a clear decline of
HIV prevalence among Female Sex Workers in most of the
states. However, the evidence shows that IDU and Men
having sex with men (MSM) populations are more vulnerable
to HIV with trend of increasing prevalence in many states.
HIV and STIs
The first data on HIV incidence in high risk populations in
India emerged from a prospective cohort of sexually
transmitted disease (STD) clinic attendees in Pune. The
overall HIV sero-prevalence among STD clinic attendees
at screening was found to be 21.2% (1993–1995) with
alarmingly high incidence rates of 9.6% among male STD
patients, and 26.1% among commercial sex workers [8].
Incidence rate of 4.6% was reported among women who
were not engaged in sex work and did not have any high-
risk behaviour of their own [9]. Their only risk factor was
being married to a person with high risk behaviour
Fig. 1 State wise estimated
adult HIV prevalence in India—
2009 (Based on NACO) [6]
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highlighting the need for interventions among women. The
cohort studies at NARI also highlighted the role of various
other sexually transmitted infections in HIV transmission.
Ulcerative and non ulcerative STDs increase the risk of
HIV acquisition and incident HSV-2 infection increases the
risk of HIV-1 acquisition three times [10] while incident
syphilis increases the risk 4.44 times [11]. While these data
have highlighted the importance of STI treatment and
control for HIV prevention, studies using multiplex PCR
techniques for diagnosis of genital ulcers not only dem-
onstrated multiple aetiologies but also supported the use of
syndromic treatment in the control program.
Other risks for HIV Infection: Migration, Driving Long
Distance Trucks
‘Most at Risk Populations’ (MARPS) are the populations
most vulnerable to HIV like sex workers (both male and
female), MSM and IDU. Additionally single male migrants
and long distance truck drivers are also more vulnerable
and they along with male clients of sex workers and STD
patients form the populations that bridge the high risk
groups to the general population.
Migration is now increasingly recognised as an impor-
tant facilitator of the spread of HIV infection in India as
well as other parts of the world. Districts in Maharashtra
with high in and out migration have also been identified as
having high HIV prevalence [12]. Data from IBBA survey
round–I conducted among 2,066 long distance truckers in
India revealed an HIV prevalence of 4.6% [13]. The data
collected from long distance truck drivers indicated low
self-risk perception for HIV (9.9%), low consistent condom
use with non-paid partners (18.6%) and wives (3%), low
reported exposure to any interventions (25.6%) and low
levels of ever having taken an HIV test (16.5%). These
observations emphasize the need for strengthening of
interventions in this important bridge population.
HIV and Tuberculosis
Tuberculosis is not a risk factor for HIV infection. How-
ever, HIV infected individuals with compromised immune
system commonly suffer from tuberculosis. Increasing
trend of HIV prevalence was observed among newly
diagnosed tuberculosis patients in Pune, from 3.2% in 1991
to 20.1% in 1996 [14]. However prevalence of HIV among
newly diagnosed Tuberculosis patients varies across the
states [15, 16]. The ‘‘lifetime risk’’ of developing active
tuberculosis in immune-competent persons is 5–10%,
however in HIV infected individuals there is a 5–15%
‘‘annual risk’’ of developing active TB disease. There are
data indicating chemoprophylaxis for tuberculosis reducing
the incidence of active TB in HIV infected individuals.
However various operational issues are still unresolved for
inclusion of TB prophylaxis in the programme. Recog-
nizing the association of TB and HIV, the National AIDS
Control Programme (NACP) and Revised National
Tuberculosis Control Programme (RNTCP) have encour-
aged the cross referrals to bring TB patients with HIV
infection under HIV care programmes.
Transfusion and HIV
While transfusion transmitted infections have decreased
considerably with the focused and intensive blood safety
strategy by NACO; persons requiring repeated blood
transfusions like haemophiliacs, are still vulnerable to HIV
infection and need to be educated about accessing trans-
fusions only from authorized blood banks.
HIV-2 Infection
In India the HIV-2 infections constitute a very small (\2%)
proportion of all HIV infections [17, 18], however higher
percentages (6%) have been reported in Mumbai [19].
HIV-2 infection is reported to follow a relatively slow
disease progression. Although HIV-2 infections are rela-
tively minor, discriminating between HIV-1 and HIV-2 is
critical for initiating anti-retroviral treatment.
Structure of HIV
HIV is a lentivirus that belongs to the family Retroviridae.
The name ‘lentivirus’ means ‘slow virus’ because they take
long time, often many years to produce any adverse effects
in the host. These viruses have single stranded RNA gen-
ome and an enzyme called reverse transcriptase.
HIV has an envelope composed of phospholipid bilayer
drawn from the host cell membrane and the HIV Env
protein gp160; composed of gp120 and gp41. While gp120
is external protein and contains sites that bind CD4 and co-
receptors on the surface of human CD4 T cells, gp 41 is
membrane bound protein. The viral core or capsid is
composed of protein p24. The layer between the envelope
and the capsid i.e., matrix is composed of the protein p17.
The bullet-shaped viral capsid contains two positive
strands of RNA and the three enzymes required for HIV
replication, reverse transcriptase, integrase and protease
(Fig. 2).
HIV genome is approximately 9.1 Kb in size. It has nine
genes (structural, regulatory and accessory) and long ter-
minal repeat (LTR) region at either end of the genome
(Fig. 3).
The three structural genes gag, pol and env code for the
structural proteins for new virion and include Env protein
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(Env), capsid and matrix proteins (Gag) and enzymes in-
tegrase, protease and reverse transcriptase (Pol).
The regulatory genes tat, rev and nef are essential for
virus replication.
The accessory genes vif, vpr and vpu (or vpx in the case
of HIV-2), are also important in virus replication.
Each strand of HIV RNA contains an RNA sequence
called the long terminal repeat (LTR) at both the ends. The
LTRs act as switches to control production of new viruses
and can be triggered by proteins from either HIV or the
host cell (Fig. 3).
HIV-1 is closely related to Simian Immunodeficiency
Virus (SIV) prevalent in populations of wild chimpanzees
in West-Central Africa and is believed to have been
transmitted to humans between 1930 and 1950.
Due to lack of proof reading ability of Reverse Trans-
criptase enzyme, HIV shows very high mutation rate. As a
result of high mutation rate, HIV-1 virus strains show
extreme genetic divergence and have been classified into
nine subtypes (A–D, F, H–K), more than 30 circulating
recombinant forms (CRFs) and innumerable unique
recombinant forms (URFs). The distribution of subtypes is
largely geographically restricted such as HIV-1 Subtype A
in Africa, Subtype B in North and South Americas and
Europe, Subtype C in India, China and South Africa [4].
Indian HIV Strains
HIV molecular epidemiology studies carried out in differ-
ent parts of India suggest that subtype C is the most pre-
valent among all HIV-1 genetic subtypes [20–23]. Sporadic
presence of HIV-1 subtypes A and B has been reported in
different parts of the country. Thai B subtype was shown to
be circulating in North Eastern states, especially Manipur.
However the proportion of Thai B subtype decreased over
time among IDU’s in Manipur. Thai B subtype was grad-
ually replaced by Indian subtype C [23, 24].
Besides different subtypes, first recombinant A/C
mosaic virus was reported in India in 1998 [25]. The
Fig. 2 Structure of HIV
Fig. 3 HIV genome
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recombinant strains (A/C, B’/C) have since been reported
from different parts of the country [4]. Although HIV-1
epidemic in India has spread to practically all states over
last 20 years the Indian HIV-1 subtype C strains have
shown a remarkable homogeneity. Analysis of HIV-1
subtype C genome sequences from India showed that these
sequences were closely related to each other. These viruses
are likely to be descendents of a single founder strain that
was introduced in the beginning of the epidemic in India
[26–28]. Lower genetic divergence has also been reported
in other studies. It has been shown that the majority of
Indian subtype C sequences cluster away from subtype C
from other countries [27, 29–32].
The association of the genomic structure with the clin-
ical presentation has been shown in a study conducted by
Ranga et al. [33]. They have shown that the six amino acid
residues are differentially conserved in subtype C Tat gene.
Of these, cysteine (at position 31) was highly conserved
([99%) in non-subtype C viruses while more than 90% of
subtype C viruses show a serine substitution. The authors
indicated, although not conclusively, that this mutation
might be responsible for the lower incidence of HIV
Associated Dementia (HAD) in India.
Only one study compared the viral fitness of strains of
HIV-1 subtype C and A from India. The in vitro replication
fitness and transmission efficiency of primary isolates of
HIV-1 subtypes C was higher than subtype A primary
isolates [34]. This probably explains the predominance of
subtype C strains in spite of introduction of subtype A
strains in India more than decade and half ago.
Pathogenesis of HIV Infection
The natural course of HIV infection in India seems to be
similar to the course described in other parts of the world;
however, it has been shown that the Indian patients rapidly
progress to the symptomatic disease after sero-conversion
in a closely monitored cohort [35]. The observations from
the same cohort described that fever, night sweats, and
arthralgia as symptoms that may be predictive of recent
HIV infection [36]. It has been observed that the patients
with acute HIV infection in India showed plasma viral load
values similar to those reported from the other parts of the
world (unpublished observation). The observed median
incubation period for progression from HIV infection to
AIDS was 7.9 years, from AIDS Related Conditions
(ARC) to AIDS was 1.9 years and the median survival time
after developing AIDS was 19.2 months [37]. The data on
natural history of HIV infection have shown that the dis-
ease progression is variable amongst the infected individ-
uals. The viral and host factors play important role in the
disease progression. Besides the innate immune responses
and genetic factors the HIV-specific adaptive immune
response has been shown to play very significant role in
disease progression in HIV infection.
A case control study of 44 HIV seroconvertors and
their matched HIV negative STD patient controls nested
within the high risk STD cohort in Pune showed evidence
of an independent association between low serum beta
carotene levels and increased risk of heterosexual acqui-
sition of HIV. The authors hypothesised that low vitamin
A and carotenoid levels could increase risk by either
altering the mucous membrane integrity or due to immu-
nologic dysfunction [38]. The roles of other micronutri-
ents in the disease progression have been studied across
the world.
Hepatitis B and C (HBV and HCV) are very important
co-infections that may influence the disease progression.
The high risk HIV seronegative cohort at NARI revealed a
high incidence of HBV (10.86 per 100 person years of
follow up) [39]. Tattooing, history of being in commercial
sex work and history of a genital ulcer were identified as
being independently associated with a positive anti-HBc
antibody test. These findings underline the need for Hep-
atitis B testing and vaccination programs among the most
at risk populations (MARPs).
Although the evidence for sexual transmission of HCV
is equivocal, HIV and HCV co-infections are more pre-
valent among IDUs with the primary driver being unsafe
injecting practices. A study in Mizoram has identified
prevalence of HCV antibodies in 71.2% HIV patients. A
strong association was observed with the type of drugs
injected (p = 0.001), frequency of injecting (p = 0.013),
multiplicity of drugs used (p = 0.004), and needle syringe
sharing (p = 0.003). There was no association with num-
ber of sexual partners or age at first sex or the type of
sexual partners in the study [40].
Innate Immune Response
There is paucity of data on the innate immune response in
India. Two studies published from India shed some light on
the role of dendritic cells (DC) in HIV infection. Both
studies have shown that the plasmacytoid dendritic cells
(pDC) and myeloid dendritic cells (mDCs) were signifi-
cantly reduced in HIV infection and correlated negatively
with plasma viral load [41, 42]. Singh et al. have shown
that there is irreversible loss of pDCs in early HIV infec-
tion and in AIDS stage. The loss of pDCs is primarily due
to apoptosis. The decline seen in mDCs in AIDS stage
appears primarily due to cell migration and is reversible on
anti-retroviral treatment (ART). The decline in pDC
numbers may be responsible for down regulation of innate
immune responses.
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Host Genetic Factors
There is paucity of data on the genetic factors associated
with HIV infection and disease progression. The Indian
data has showed that in Western Indian population,
Cw*1507, B*3520, and B*1801 class I HLA alleles and
DRB1*0902-DQB1*030103 Class II alleles were signifi-
cantly associated with HIV infection [43, 44]. Asian Indi-
ans have been reported to have extreme diversity in the
MHC region, with several novel and unique alleles and
disease-associated MHC haplotypes. CCR5 Delta 32 vari-
ant is rare and Indian population generally has low
CCL3L1 copy numbers [45]. Systematic population based
studies are needed to understand the impact of host
genetics on HIV disease progression in India population.
HIV-specific Immune Response in HIV Infected Indians
HIV infection causes immune suppression as a result of the
destruction of CD4? T lymphocytes that are central to
immunoregulation. HIV infection causes the loss of CD4?
T cells, both HIV infected and HIV uninfected bystander
cells. Immune activation has been considered to be the
major cause of disease progression and CD4? T cell
decline in HIV infected individuals.
Although HIV infection leads to the loss of CD4? T
cells and immune suppression, the host immune response
may be critical for the control of viremia in HIV infected
persons. Long term non-progressors (LTNPs), about 5%
among all HIV infected, show robust immune response and
control virus multiplication successfully. Elite controllers
are individuals who suppress plasma viremia completely in
absence of anti-HIV treatment and present strong anti-HIV
immune responses [46]. Hence the LTNPs and Elite con-
trollers may provide clues about the immune mechanisms
important for vaccine development.
Data on the immune response among Indian HIV
patients is very limited.
HIV-Specific Cytotoxic T Lymphocytes (CTL)
response
The HIV-specific CTL response has been shown to be
important in controlling HIV multiplication [47, 48]. The
studies on HIV-specific CTL response in Indian patients
have reported Gag as most targeted antigen [49, 50]. The
epitopes recognized by Indian patients mainly resided
within Gag (p17 and p24 region) and Nef region. Common
immune-dominant regions were found to be recognized by
the subtype C infected population from India, South Africa
and Botswana. However, differential clustering of the
immune-dominant region was also observed which may
reflect differences in the circulating strains and class I HLA
constitutions of the study population [51]. It is crucial that
the studies are carried out with aim to identify the antigen/
epitopes that can induce robust and sustainable CTL
response.
Neutralizing Antibody Response
The anti-HIV neutralizing antibody responses have been
investigated in a small number of studies in India [52–54].
The results show that the neutralizing antibodies may
appear early in HIV infections, but their significance in
controlling early virus multiplication is not known [52].
Envelope structures from newly transmitted viruses in
India are antigenically complex in spite of close genetic
similarity. Delineation of neutralization cluster-associated
amino acid signatures; 19 in gp120 and 14 in the ectodo-
main and cytoplasmic tail of gp41 provides a deeper
understanding of the antigenic structure of HIV-1 envelop
[53]. Another study estimated neutralizing antibody
responses in asymptomatic HIV seropositives. Plasma
samples from Indian HIV-1 infected persons were able to
neutralize the autologous as well as other viruses isolated
from different parts of India [54]. This observation may
underline extensive sharing of neutralizing antibody
determinants; thus providing a window of opportunity for
immunological interventions such as vaccine. The anti-
HIV neutralizing antibodies are crucial in generating ster-
ilizing immunity at the portal of entry of the HIV i.e., at the
mucosal surface. Studies to identify the targets of neu-
tralizing antibodies that are extensively cross-reactive may
help in development of effective vaccine.
Clinical Profile in Adult HIV Infected Individuals
in India
HIV infection passes through three stages of disease pro-
gression. The period immediately after acquiring HIV
infection is an acute primary HIV infection that lasts for
about 3–6 weeks and is also known as ‘‘Window period’’.
Subsequently starts a long period of chronic disease that
may last on an average for 7–10 years and the third stage of
‘‘AIDS’’ that may last for few years in absence of anti-
retroviral treatment. The opportunistic infections are
notably seen during AIDS stage and less frequently during
chronic stage of the infection.
Although HIV epidemic has progressed over last
25 years, there is no systematically collected data on the
clinical presentations and natural history of HIV infection
in India. The HIV epidemic in India is geographically
diverse and there are regional differences, not only in the
incidence and prevalence of HIV infection, but also in the
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clinical presentations and profile of opportunistic infections
(Table 1). However, pulmonary and extra-pumonary
tuberculosis, oral candidiasis, cryptococcal meningitis and
pneumocystis jiroveci pneumonia are some of the com-
monest occurring opportunistic infections. There is prac-
tically no data on the malignancies associated with HIV
infection in Indian setting.
HIV and HPV
Studies among HIV infected women have shown that a
significant proportion carry cervical precancerous lesions
which can progress to invasive cancers if left undiagnosed
and untreated [55].
A very high prevalence of high risk oncogenic HPV
subtypes (16 & 18) has been demonstrated in Pune (41.7%)
and Kolkata (32.2%) among HIV infected women as
compared to the uninfected. The morbidity due to anal
HPV in MSM and the role of HPV in head neck cancers
among the HIV infected persons are under study. Cost-
effective strategies for early diagnosis and intervention for
pre-cancerous lesions need to be scaled up within the
treatment and care programmes for HIV infected in India.
Clinical Profile in HIV Infected Children
The studies on clinical manifestations in HIV infected
children have been carried out in various parts of the
country. A study from Mumbai reported protein energy
malnutrition, pulmonary and extra-pulmonary tuberculosis,
hepato-splenomegaly, persistent generalized lymphade-
nopathy, chronic diarrhoea, oral thrush, pyrexia of unknown
origin, chronic lung disease, chronic hypertrophic parotitis,
chronic ottorrhea, recurrent lower respiratory tract infec-
tion, neurological manifestations and Pneumocystes jiro-
veci pneumonia in HIV infected children [56]. The common
opportunistic infections observed in a study from Karnataka
were tuberculosis, recurrent diarrhoea, oral candidiasis and
recurrent bacterial pneumonia [57]. A recently published
report from south India showed oral candidiasis, gingivitis,
oral pigmentation, depapillation of the tongue, ulcers, and
oral hairy leukoplakia in HIV infected children. The most
common systemic lesion observed in this study was non-
specific lymphadenopathy followed by pruritic eruptions,
measles, and tuberculosis [58].
Diagnosis of HIV Infection
Diagnosis of HIV infection can be carried out either by
detecting antibodies to HIV antigens or p24 HIV antigen in
serum or plasma or by demonstrating the HIV nucleic acid
(DNA or RNA) in peripheral blood mononuclear cells or
plasma. HIV antibody testing in serum/plasma using assays
such as Enzyme Immuno Assays (EIAs) is the most com-
monly used method to diagnose HIV infection. HIV EIAs
have become increasingly more sensitive and specific since
HIV testing began in 1980s. The national guidelines in
India recommends using three HIV antibody detecting tests
with different HIV antigens / different principles in suc-
cession to confirm HIV infection. In case of discordance it
is required to confirm HIV antibody status using a confir-
matory test such as Western Blot or Line Immunoassay
(LIA). In such situation it is mandatory that the test kits
used as a first screening tests are very sensitive.
HIV Diagnosis in Patients Within Window Period
In case of the patients who have been infected recently and
hence have not developed antibodies yet, the diagnosis of
the HIV infection can be carried out using DNA PCR, or
the quantitative HIV RNA PCR. P24 antigen detection can
also be used in such cases. However, it is important to
remember that the presence of p24 is transient and it may
not be present in all patients with recent HIV infection.
Hence the diagnostic utility of the p24 antigen detection is
limited.
Table 1 Profile of opportunistic infections in HIV infected individuals in India
Authors Geographic location Opportunistic Infections
Kumarasamy et al. [93] Chennai, South India Pulmonary tuberculosis, Pneumocystis jiroveci pneumonia, cryptococcal
meningitis, central nervous system toxoplasmosis
Vajpayee et al. [94] Delhi, North India Tuberculosis, parasitic diarrhea and oral candidiasis
Singh et al. [95] Manipal, South India Oral candidiasis, tuberculosis, Cryptosporidium infection and Pneumocystis
jiroveci pneumonia
Ghate et al. [96] Pune, West India Tuberculosis, cryptococcal meningitis, oral candidiasis, CMV retinitis
Charkravarty et al. [97] Varanasi, Eastern India Tuberculosis, oropharyngeal candidiasis, diarrhoea
Saldanha et al. [98] Karnataka, South India Tuberculosis, candidiasis, cryptosporidiosis and cryptococcal meningitis
Saha et al. [99] Calcutta, North East India Oral candidiasis, Cryptococcal diarrhoea, cytomegalovirus and Herpes
simplex virus-2
Proc. Natl. Acad. Sci. Sect B. Biol. Sci. (January–March 2012) 82(1):167–180 173
123
HIV Diagnosis in Infants and Children
Diagnosis of HIV infection in babies born to HIV-infected
mothers cannot be established by conventional antibody
tests due to the presence of maternal anti-HIV antibodies in
the circulation in child. These maternal antibodies may
persist in the infant for as long as 18 months. Hence, HIV
DNA-PCR or HIV RNA PCR is used for diagnosing HIV
infection in children younger than 18 months. WHO rec-
ommends two positive HIV-1 DNA or RNA assay results at
6 weeks after birth (sensitivity [98%) for the definitive
diagnosis of HIV-1 infection (WHO guideline). The whole
blood sample is required for these assays; however some
DNA and RNA PCR assays support the use of dried blood
spot (DBS) samples, which have considerable advantages in
settings where sample transportation and storage are a
challenge. The National AIDS Control Program (NACP-III)
has implemented the dried blood spots for DNA PCR test-
ing in infants in 26 states under the government settings.
External Quality Assurance
It is extremely important to monitor the quality of the
testing at every level. The testing laboratory must partici-
pate in the External Quality Assurance Scheme (EQAS)
run by any external agency. The successful participation in
the EQAS gives a confidence to the testing laboratories,
offers trouble shooting and ensures generation of correct
results. The National AIDS Control Organization (NACO)
runs such EQAS programme for the laboratories under
government programme through a network of laboratories
with NARI as an apex laboratory.
Monitoring of HIV Disease Progression
The CD4? T cell count is used as a marker of immune-
suppression to decide when to initiate the antiretroviral
therapy (ART), to monitor the success of ART and to
decide when to initiate chemoprophylaxis for opportunistic
infections. The plasma viral load estimation is the best
indicator of how active HIV is in the patient’s body,
whereas the absolute CD4 cell count is more predictive of
clinical disease progression. In the beginning of HIV
epidemic, various other markers such as b2 microglobulin,
neopterin and various cytokines have been considered as
the surrogate markers to monitor the disease progression
[59–63]. Although nonspecific, these makers gave fairly
good idea about the immune activation and thus the disease
progression in HIV infected individuals.
Anti Retroviral Treatment in India
In early period of HIV epidemic in the country, a contin-
uum of care for HIV/AIDS focused on medical care,
counselling and psychosocial support. HIV/AIDS medical
care included clinical examination, diagnosis & treatment
of opportunistic infections and referral of terminally ill
patients to the tertiary care hospitals. CD4 count and viral
load testing were unaffordable services for most HIV/AIDS
patients and were done only at limited number of centres,
such as research institutes and few private laboratories. Till
2003, it was estimated that out of 7,50,000 HIV infected
individuals requiring ART, only 13,000 (\2%) were on
ART. A study from South India reported a dramatic
decrease in mortality from 25 to 5 deaths per 100 person
years of follow up in HIV infected individuals between
1997 and 2003 as a result of highly active antiretroviral
treatment (HAART) [64].
Government of India (GOI) launched the free ART
programme on 1st April 2004. The selection of first-line
regimens under the programme is determined on the basis
of a number of considerations, such as potency, profile of
side-effects, ability to keep future treatment options open,
adherence, cost, and potential of the development of
resistant virus strains. The current global recommendation
in all circumstances is a triple drug regimen. The key goals
of the National ART programme include: providing long-
term ART to eligible patients, monitoring and reporting
treatment outcomes on a quarterly basis, attaining indi-
vidual drug adherence rates of 95% or more, to increase
life span so that 50% of patients on ART are alive 3 years
after starting the treatment and to ensure that 50% of
patients on ART are engaged in or can return to their
previous employment. The programme has established 300
ART centres all over the country and 404882 PLHIV are
Fig. 4 Mutations in the HIV-1 protease and reverse transcriptase gene associated with drug resistance that are commonly found in Indian
patients
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on ART by March 2011 [65]. The different studies done in
India to evaluate the efficacy of the antiretroviral drugs in
the programme have showed good clinical and immuno-
logical response to the therapy [66, 67].
The national programme currently provides antiretrovi-
ral drugs from nucleoside reverse transcriptase inhibitor
(NRTI) and non nucleoside reverse transcriptase inhibitor
(NNRTI) groups as first line treatment. It is a combination
of two NRTIs (zidovudine or stavudine and lamivudine)
and one NNRTI (nevirapine or efavirenz). Many countries
in the world including India have accepted WHO recom-
mendation of initiating ART when CD4 counts fall below
350 cells/cmm.
Paediatric ART in India
Studies carried out in children on generic antiretroviral
drugs in private sector showed that HAART was effective
and safe in paediatric population [68]. The Paediatric HIV
care and treatment program was officially launched in
November 2006. There was significant increase in the
number of children registered in the ART clinics of which
more than 18,000 children are receiving ART. The treat-
ment guidelines that were developed jointly by the IAP,
UNICEF, WHO and Clinton Foundation recommended the
first line ART as a combination of stavudine, lamivudine
and nevirapine. For children older than 3 years, who need
both ART and therapy for tuberculosis, efavirenz is rec-
ommended instead of nevirapine [69].
It was seen from available data that nearly 2–3%
patients on ART had developed treatment failure to the first
line drugs as reported from a rapid survey of 38 ART
centres conducted by World Health Organisation and
National AIDS Control Organization in December 2006
[70]. Second-line ART was initiated using an approach
combining clinical and immunologic evaluation with con-
firmation of virologic failure and it was reported that
inclusion of targeted HIV RNA testing in the evaluation of
treatment failure could prevent unnecessary switches to
second-line ART [71].
ARV Drug Resistance
Antiretroviral drug resistance acts as a major impediment
in the management of human immune deficiency virus
type-1 (HIV-1) infection. The adherence to antiretroviral
drugs becomes extremely important to prevent next epi-
demic of drug resistant HIV. The different studies in India
have shown the resistance pattern to antiretroviral drugs
[72] (Fig. 4).
National AIDS Research Institute in collaboration with
NACO and WHO carried out two threshold surveillance
surveys for drug resistance, among recently infected per-
sons attending voluntary counselling and testing centre in
Mumbai [72] and pregnant women in Kakinada, Andhra
Pradesh [unpublished data]. The studies confirmed that the
drug resistance mutations among recently transmitted virus
strains were seen in less than 5% of isolates. In HIV drug
resistance monitoring surveys conducted in two ART
centres in Mumbai and Chennai under the same pro-
gramme 10.3% and 7.4% respectively showed presence of
drug resistance viruses at 12 months after initiation of ART
under national ART programme [73]. This indicates that
the current free ART regimen being provided by the GOI
would be effective in majority of the subjects placed on the
free ART regimen of National programme. But adherence
remains the key issue for minimizing the drug resistance.
HIV Prevention Efforts in India
HIV prevention efforts in India have relied on risk reduc-
tion through Information, Education and Communication
(IEC), interventions promoting behaviour change and
condom use, prevention and treatment of sexually trans-
mitted infections and encouraging Voluntary Counselling
and Testing (VCT). The national programme lays emphasis
on prevention of transfusion associated transmission and
prevention of parent to child transmission (PPTCT) of HIV
infection.
Prevention of parent to Child transmission of HIV
In the absence of any interventions, approximately 15–30%
of HIV infected pregnant women transmit HIV infection to
the baby either ante-partum, during delivery or post-partum
through breast milk. However, very effective interventions
are available to prevent mother to child transmission. The
program for Prevention of transmission from Parent to
Child is a comprehensive program that focuses not only on
Fig. 5 Genetic structure of AAV2 (tgAAC09) candidate vaccine
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counselling, testing and prophylaxis intervention to prevent
transmission from mother to child, it also encompasses the
education of HIV negative mother, early diagnosis and
linkage to care of the infants born to HIV infected mother
linking the mother to care and support. Although this is one
of the most effective interventions worldwide, there is a
need to scale up the intervention. There is also a proposal
to replace the current single dose nevirapine regimen with
more potent triple drug combination. A study by NARI,
B.J. Medical College Pune and Johns Hopkins University,
Baltimore, USA has shown that the 6 weeks nevirapine
prophylaxis given to the baby is safe and has greater effi-
cacy compared to single dose nevirapine [74].
In spite of the progress achieved, only an estimated 20%
of pregnant women in 2009 were counselled and tested and
only 30% of the estimated 65,000 HIV infected pregnant
women could actually be reached [75], thus highlighting
that even the best of intervention tools are limited by dif-
ficulties in implementation.
Blood Safety
Over last few years, the Blood Safety program has taken
many steps to improve the quality of blood for transfusion,
by introducing mandatory testing of blood and blood
products for HIV, Hepatitis B & C, Syphilis and Malaria.
Current methods of donor screening and testing of donated
blood have led to a decrease in the incidence of the
transfusion-transmitted infections as well as HIV preva-
lence as reported by blood banks.
HIV Vaccine Research
While the national programme has relied on the risk
reduction approach, a number of efforts are being made to
apply newer prevention technologies like vaccines and
microbicides for prevention of HIV infection.
A safe and effective vaccine has been the goal as well as
the major challenge for HIV research worldwide. The
preclinical studies on the development of HIV vaccine
from India primarily showed the immunogenicity of the
vector based vaccines (recombinant vaccinia expressing
Indian HIV-1 subtype C Env or Gag proteins) in the Balb/C
murine model [76, 77]. Both the studies showed generation
of HIV-specific humoral as well as cell mediated immune
response as evaluated by IFN-gamma ELISPOT assay.
Various vaccine candidates such as DNA vaccine
expressing HIV-1 C Gag, the DNA vaccine expressing
multiple CTL epitopes are being evaluated.
Three phase I human vaccine trials have been success-
fully conducted in India. The first Indian vaccine trial
conducted at NARI Pune in 2005 was a dose escalation
Phase I study using the Adeno-Associated Virus recombi-
nant vaccine (tgAAC09) (Fig. 5) which expressed HIV-1
subtype C gag protease and RT genes; was found to be safe
in humans but did not generate adequate immune response
[78].
A recombinant Modified Vaccinia Ankara expressing
env, gag, tat, rev, nef and RT genes from Indian clade C
virus (MVA-TBC M4) was developed under the Indian
Council of Medical Research, NACO and International
AIDS Vaccine Initiative collaborative vaccine programme.
This vaccine underwent phase I human clinical trial at
Tuberculosis Research Centre (TRC) in 2006. This vaccine
was found to be safe and also able to elicit moderate
immune response among the volunteers [79]. This vaccine
was further tested in another trial using a prime and boost
approach at both NARI and TRC using DNA vaccine
(ADVAX) for priming and MVA-TBC M4 (Fig. 6a, b) for
boosting. This heterologous strategy was compared with the
A
B
Fig. 6 HIV vaccine candidate
used in the prime boost strategy
in clinical trial in India
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homologous boosting using only MVA (TBC-M4). The
study was completed in December 2010. Although final
results are awaited there are indications that the prime-boost
regime was safe and induced broader and stronger immune
response [80]. The moderately successful Phase III vaccine
trial (RV144) in Thailand showed that a prime boost com-
bination was about 31% effective in modified intent to treat
analysis for prevention of acquisition of HIV [81].
Microbicides and Pre-Exposure Prophylaxis
Encouraging evidences on efficacy of newer tools for
prevention have emerged on the global horizon recently. A
1% gel formulation of tenofovir, anti-retroviral drug, as a
vaginally applied microbicide showed 38% reduction of
HIV incidence among women using the gel 50–80% of the
times [82] and oral pre-exposure chemoprophylaxis using
oral Tenofovir and Emtricitabine combination pill among
men having sex with men [83] showed over 50% protec-
tion. In India, where monogamous women continue to
experience risk through the behaviours of their spouses,
microbicides can be an important prevention tool, which
will have to be scaled up along with behavioural inter-
ventions to empower women. Acceptability of women
controlled prevention tools among both men and women is
an important determinant that has been explored in India
[84–86]. Indigenously developed microbicides like the
Neem based ‘Praneem’ and curcumin based ‘BASANT’
have undergone early phase trials in India and many studies
on acceptability of these and other microbicides have also
been conducted [87–92].
India should be poised to accept and scale up newer
preventive tools in a manner acceptable and feasible in our
socio-cultural context in order to sustain and consolidate
the gains that we have achieved so far.
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